Medifast trades below net cash, with an EV of -$43.68M, reflecting deep skepticism about its OPTAVIA MLM business and turnaround prospects. GLP-1 drugs have rendered MED's weight-loss model largely ...
Medifast® (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system OPTAVIA, celebrates the inspiring health transformation of Tiffany Howard, recently ...
11monon MSN
Medifast outlines 2025 priorities with plans for $15M-$20M cost savings and new product expansions
Q4 2024 Management View CEO Dan Chard highlighted that 2024 was a transformative year for Medifast due to the increasing adoption of GLP-1 weight loss medications. The company is adapting to these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results